Past 28 days open, or past the printed expiry
3 min read FDA Moves to End Compounded Semaglutide and Tirzepatide What It Means for Weight Loss Patients The FDA Just Proposed a Major Change to Compounded Weight Loss Drugs If you've been following the news about weight loss medications, you may have heard that the FDA announced a significant regulatory change on April 30, 2026
Vitamin injections in Dallas provide speedy, concentrated benefits by injecting vitamins directly into the muscles
Semaglutide mimics a hormone called GLP-1, which is essential in regulating appetite and food intake
Semaglutide reduces blood glucose in a glucose dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high
BPC-157 is locally acting - targets injury site through growth factor and fibroblast pathways, dosed in micrograms (250500 mcg), given twice daily